Researchers screening blood donors during Argentina's western equine encephalitis outbreak found one donor carrying the virus in their bloodstream with no symptoms, a finding published in the CDC journal Emerging Infectious Diseases.
Western equine encephalitis virus reemerged in Argentina and Uruguay in late 2023 after nearly three decades without a confirmed human case in Argentina. Across the two countries from November 2023 through April 2024, the regional outbreak produced 217 human cases, 12 of them fatal, along with 2,548 equine cases. Argentina's own confirmed human count for the outbreak has been reported as 107 cases with 12 deaths, a lower figure that reflects the narrower national scope rather than a contradiction.
The single asymptomatic donor is the detail that carries beyond South America. A person who feels fine and donates blood cannot be screened out by asking about symptoms, and that is precisely the scenario blood safety systems are built to catch. There is no U.S. outbreak and no change to American blood donation rules, but the finding is the kind of evidence that shapes how agencies prepare for one.
One Donor Out of 637
The study team assessed the effect of viral circulation on the blood supply by building interventions into a regional hemovigilance system, including epidemiologic mapping, enhanced donor selection criteria, and alphavirus-specific nucleic acid testing.
Of roughly 4,000 people who donated during the intervention period, 637 lived in areas mapped as having suspected virus circulation. Testing of samples from that group identified one asymptomatic viremic donor. Phylogenetic analysis placed the viral sequence within the contemporary South American outbreak lineage, consistent with ongoing regional transmission. The authors described blood donors as a sentinel population for detecting silent circulation that symptom-based surveillance can miss.
A separate study in the same journal issue documented the outbreak on the animal side. During November 2023 through April 2024, Argentine authorities received reports of 1,543 horses with neurologic disease across 17 provinces. Testing of brain tissue confirmed the virus in 23 horses and one sheep. Researchers also collected mosquitoes in Santa Fe Province, one of the most affected areas, and found three of 27 mosquito pools positive, two in Aedes albifasciatus and one in Aedes scapularis. The authors noted that decades without reported cases likely delayed early recognition of the outbreak, that transmission is difficult to control without widespread equine vaccination, and that the ecological and environmental drivers of the virus's return need further study.
The AABB, the professional association for blood banking, reviewed the donor finding through its transfusion-transmitted diseases committee and described it as both expected and consistent with reports from outbreaks of other arboviruses, including West Nile virus, dengue, and St. Louis encephalitis.
That context is important and runs counter to the alarm. Finding one viremic donor among 637 in an active outbreak zone is not surprising. It is confirmation that a known pattern applies to this virus, too.
The Reason Blood Banks Watch Mosquito Viruses
The reason arboviruses matter to blood supplies comes down to timing.
Most people infected with these viruses have no symptoms or only mild ones, and the virus circulates in the bloodstream for a window before the immune system clears it. Someone in that window feels healthy enough to donate. Standard donor questionnaires screen for illness, travel, and risk behaviors, and none of those catch a person who has no idea they were infected.
The United States learned this with the West Nile virus. After transfusion-transmitted cases were documented in 2002, blood centers began nucleic acid testing of donations the following year, which detects viral genetic material rather than the antibody response. That system has been in place for years, and it is why West Nile is no longer a meaningful transfusion risk here, despite being widespread each summer.
Western equine encephalitis has no such dedicated screening program in the United States, and there are no specific donor deferral criteria for it, because the virus has been nearly absent for decades. Human cases in this country have been very rare in recent decades. There is also no licensed human vaccine and no specific antiviral treatment, though inactivated vaccines are used in horses.
That combination is what makes surveillance work like this relevant to U.S. preparedness. The question a blood safety system has to answer before an outbreak, not during one, is whether a test exists, whether laboratories can run it, and what geographic triggers would prompt deferral or testing.
The Argentine team's approach is instructive on that point precisely because it was assembled during an outbreak rather than in advance. They combined epidemiologic mapping to identify affected areas, tightened donor selection criteria, and added alphavirus-specific molecular testing. Each of those steps requires time and laboratory capacity that a blood system does not want to build while donations are already flowing.
The Practical Picture for U.S. Readers
Nothing in this changes whether anyone should give blood.
There is no current U.S. outbreak of western equine encephalitis, no change in donor eligibility, and no reason to defer a donation. The U.S. blood supply operates with layered safeguards, including donor screening, testing for multiple agents, and pathogen reduction technology for some components. Blood shortages are a recurring and immediate problem, and discouraging donation over a South American research finding would cause more harm than the risk it addresses.
For travelers, the relevant precaution is the ordinary one. Anyone visiting affected areas of Argentina, Uruguay, or southern Brazil during their mosquito season, which runs opposite to the northern hemisphere summer, should use an EPA-registered repellent, wear long sleeves, and use screens or air conditioning. There is no vaccine to seek.
Most people infected with the western equine encephalitis virus have no symptoms, and illness, when it occurs, is often limited to fever, headache, and muscle aches. A smaller share develops encephalitis, or inflammation of the brain, which is the outcome that produced the deaths in this outbreak, and which published estimates place at a 5% to 15% fatality rate. Infants and older adults face a higher risk of severe disease. Anyone who develops fever with confusion, severe headache, neck stiffness, or seizures after travel to an affected area should seek urgent care and mention the travel history.
The mosquito-borne diseases actually circulating in the United States this summer are the ones worth household attention, and MedicalDaily has reported that West Nile is running well ahead of recent seasons as transmission enters its heaviest weeks.
What remains unresolved is whether transmission in South America continues and whether the virus spreads further. The current issue of the CDC journal carries both the donor study and the equine investigation.
Key Questions Answered
What did researchers find? Among 637 blood donors in areas affected by Argentina's western equine encephalitis outbreak, one asymptomatic donor had the virus circulating in their blood.
Why does that matter? Someone with no symptoms cannot be screened out by questions about illness, which is the scenario blood safety testing is designed to address.
Is the U.S. blood supply at risk? There is no current U.S. outbreak, no change to donor eligibility, and no reason to avoid donating. The blood supply uses layered safeguards.
How big was the outbreak? Across Argentina and Uruguay, the regional outbreak produced 217 human cases, 12 of them fatal, alongside 2,548 equine cases.
Is there a vaccine? Not for humans. Inactivated vaccines are used in horses, and there is no specific antiviral treatment for people.
What are the symptoms? Most infections cause none. Illness can range from fever and headache to encephalitis, which is inflammation of the brain. Infants and older adults face higher risk.
What should travelers do? Use EPA-registered repellent, cover up, and use screens or air conditioning in affected areas. Seek urgent care for fever with confusion, severe headache, neck stiffness, or seizures after travel.
